13G Filing: Nantahala Capital Management and Aeglea Bio Therapeutics Inc (AGLE)

Page 6 of 7 – SEC Filing

CUSIP NO.  00773J103 Page
6 of 7 Pages
Item 4(c). Number of shares as to which such person has:
 

Nantahala Capital Management, LLC

(i) Sole power to vote or direct the vote 0
(ii) Shared power to vote or to direct the vote 1,813,573
(iii) Sole power to dispose or to direct the disposition of 0
(iv) Shared power to dispose or to direct the disposition of 1,813,573
Each of Messrs.
Harkey and Mack:
(i) Sole power to vote or direct the vote 0
(ii) Shared power to vote or to direct the vote 1,813,573
(iii) Sole power to dispose or to direct the disposition of 0
(iv) Shared power to
dispose or to direct the disposition of
1,813,573
Item 5. Ownership of Five Percent or Less of a Class:
This Item 5 is not applicable.
Item 6. Ownership of More than Five Percent on Behalf of Another Person:
Nantahala Capital Partners SI, LP, a fund advised by Nantahala, has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, approximately 5.3% of the outstanding shares of common stock beneficially owned by Nantahala  reported herein
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company:
Each of Messrs. Harkey and Mack is filing this Schedule 13G as a control person in respect of shares beneficially owned by Nantahala, an investment adviser as described in §240.13d-1(b)(1)(ii)(E).  See Item 4(a).
Item 8. Identification and Classification of Members of the Group:
This Item 8 is not applicable.
Item 9. Notice of Dissolution of Group:
This Item 9 is not applicable.

Follow Spyre Therapeutics Inc. (NASDAQ:SYRE)